The British pharmaceutical company GSK has sold its remaining stake in Haleon for 1.25 billion pounds, thus completing the gradual divestment of shares in the company that emerged from a joint venture with Pfizer in 2019.

GSK announced that 385.3 million shares of Haleon were sold at a price of 324 pence per share. The sale price was 2.5 percent below Haleon's closing price of 332.40 pence on Thursday. GSK has been continuously reducing its stake in Haleon since May last year.

At the same time, the US pharmaceutical giant Pfizer reduced its stake in Haleon from 32 percent to 22.6 percent in March.

Haleon was formed in July 2019 through the merger of the consumer healthcare divisions of GSK and Pfizer.

In July 2022, the company was spun off and listed on the London Stock Exchange.